PubRank

Effects of Coenzyme Q10 (CoQ) in Parkinson Disease (QE3)

Clinical Trial ID NCT00740714

PubWeight™ 12.55‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00740714

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2004 17.79
2 Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005 12.09
3 Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002 4.60
4 Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993 3.40
5 A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007 2.32
6 Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003 2.04
7 Calcium signaling and neurodegenerative diseases. Trends Mol Med 2009 2.03
8 A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol 2014 1.78
9 Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011 1.66
10 Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000 1.56
11 Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord 2012 1.36
12 Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 1997 1.34
13 Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002 1.22
14 Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 1998 1.19
15 Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 2004 1.11
16 Concurrent administration of coenzyme Q10 and alpha-tocopherol improves learning in aged mice. Free Radic Biol Med 2005 1.10
17 Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat 2009 1.01
18 Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res 2002 0.98
19 Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 1994 0.97
20 Review of clinical trials for mitochondrial disorders: 1997-2012. Neurotherapeutics 2013 0.94
21 Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 2014 0.92
22 Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection. Parkinsons Dis 2010 0.86
23 Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998 0.86
24 Novel targets for mitochondrial medicine. Sci Transl Med 2016 0.82
25 Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003 0.82
26 High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med 2005 0.82
27 Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs. Int J Toxicol 2012 0.77
28 Mitochondrial therapy for Parkinson's disease: neuroprotective pharmaconutrition may be disease-modifying. Clin Pharmacol 2010 0.75
Next 100